Immune checkpoint inhibitors (ICI): toxicity management
Evidence-based neurology checklist on immune checkpoint inhibitors (ici): toxicity management: Autoimmune tests NMDAR Caspr1 Anti-MOG Anti-NMO Paraneoplastic Anti AChR Anti-MUSK Anti-ganglioside Myositis panel Other blood tests Other investigations Treatment
Autoimmune tests
- NMDAR
- Caspr1
- Anti-MOG
- Anti-NMO
- Paraneoplastic
- Anti AChR
- Anti-MUSK
- Anti-ganglioside
- Myositis panel
Other blood tests
Other investigations
Treatment
References
- Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S. How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 2019; 4(Suppl 4):e000540.
- Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 2018; 18:3.
- Thummalapalli R, Sena LA, Probasco JC, Gladstone DE. Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma. Leuk Lymphoma 2020; 61:228-230.
